Sanofi US

Part of Sanofi

CompanyUnited States

Sanofi US develops one asset, approved (lixisenatide in type 2 diabetes). Mostly peptide acting on GLP1R; based in the United States.

1
Asset
Furthest stage
Approved
0
Trials
12
Signals

Pipeline

1
  • lixisenatide

    Glucagon-like peptide-1 (GLP-1) receptor agonist improving glycemic control

    Approved, Peptide, GLP1R, type 2 diabetes, acute coronary syndrome (Phase 3)

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms2
  • Signals20
  • Similar companies6

Papers

Intelligence